Cargando…

Disease burden of spinal muscular atrophy in Germany

BACKGROUND: This study aimed at analyzing the economic burden and disease-specific health-related quality of life (HRQOL) of patients with spinal muscular atrophy (SMA) in Germany. SMA is a so far non-curable neuromuscular disease of the anterior nerve cells that causes high rates of morbidity and m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Klug, Constanze, Schreiber-Katz, Olivia, Thiele, Simone, Schorling, Elisabeth, Zowe, Janet, Reilich, Peter, Walter, Maggie C., Nagels, Klaus H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4857429/ https://www.ncbi.nlm.nih.gov/pubmed/27145956 http://dx.doi.org/10.1186/s13023-016-0424-0

Ejemplares similares

Comparative cost of illness analysis and assessment of health care burden of Duchenne and Becker muscular dystrophies in Germany
por: Schreiber-Katz, Olivia, et al.
Publicado: (2014)

Time to diagnosis of Duchenne muscular dystrophy in Austria and Germany
por: Hiebeler, Miriam, et al.
Publicado: (2023)

Nusinersen Wearing-Off in Adult 5q-Spinal Muscular Atrophy Patients
por: Osmanovic, Alma, et al.
Publicado: (2021)

Advances in Treatment of Spinal Muscular Atrophy – New Phenotypes, New Challenges, New Implications for Care
por: Schorling, David C., et al.
Publicado: (2020)

The Burden of Spinal Muscular Atrophy on Informal Caregivers
por: Aranda-Reneo, Isaac, et al.
Publicado: (2020)

Improvement of muscle strength in specific muscular regions in nusinersen-treated adult patients with 5q-spinal muscular atrophy
por: Schreiber-Katz, Olivia, et al.
Publicado: (2023)

SMArtCARE - A platform to collect real-life outcome data of patients with spinal muscular atrophy
por: Pechmann, Astrid, et al.
Publicado: (2019)

An observational cohort study on pulmonary function in adult patients with 5q-spinal muscular atrophy under nusinersen therapy
por: Bjelica, Bogdan, et al.
Publicado: (2023)

Treatment expectations and patient-reported outcomes of nusinersen therapy in adult spinal muscular atrophy
por: Osmanovic, Alma, et al.
Publicado: (2020)

Economic burden of spinal muscular atrophy: an analysis of claims data
por: Belter, Lisa, et al.
Publicado: (2020)

Burden of Spinal Muscular Atrophy (SMA) on Patients and Caregivers in Canada
por: McMillan, H.J., et al.
Publicado: (2021)

The Burden of Primary Caregivers of Spinal Muscular Atrophy Patients and Their Needs
por: Evkaya Acar, Ayça, et al.
Publicado: (2021)

Increased chitotriosidase 1 concentration following nusinersen treatment in spinal muscular atrophy
por: Freigang, Maren, et al.
Publicado: (2021)

Recent developments in Duchenne muscular dystrophy: facts and numbers
por: Walter, Maggie C., et al.
Publicado: (2017)

Spinal muscular atrophy
por: D'Amico, Adele, et al.
Publicado: (2011)

Cost of illness in inclusion body myositis: results from a cross-sectional study in Germany
por: Senn, Katja C., et al.
Publicado: (2023)

Glial fibrillary acidic protein in cerebrospinal fluid of patients with spinal muscular atrophy
por: Freigang, Maren, et al.
Publicado: (2022)

Validity and reliability of the German multidimensional fatigue inventory in spinal muscular atrophy
por: Binz, Camilla, et al.
Publicado: (2022)

Treatment satisfaction in 5q-spinal muscular atrophy under nusinersen therapy
por: Osmanovic, Alma, et al.
Publicado: (2021)

Newborn screening for spinal muscular atrophy in Germany: clinical results after 2 years
por: Vill, Katharina, et al.
Publicado: (2021)

Cognitive Performance of Patients with Adult 5q-Spinal Muscular Atrophy and with Amyotrophic Lateral Sclerosis
por: Osmanovic, Alma, et al.
Publicado: (2020)

Nusinersen for spinal muscular atrophy
por: Wurster, Claudia D., et al.
Publicado: (2018)

Spinal Muscular Atrophy and Ependymoma
por: Albakr, Aishah, et al.
Publicado: (2017)

Risdiplam for spinal muscular atrophy
Publicado: (2022)

Patient-Reported Health-Related Quality of Life, Anxiety and Depression in Patients with Inclusion Body Myositis: A Register-Based Cross-Sectional Study in Germany
por: Senn, Katja C., et al.
Publicado: (2023)

Executive function is inversely correlated with physical function: the cognitive profile of adult Spinal Muscular Atrophy (SMA)
por: Mix, Lucas, et al.
Publicado: (2021)

Serum creatine kinase and creatinine in adult spinal muscular atrophy under nusinersen treatment
por: Freigang, Maren, et al.
Publicado: (2021)

An observational cohort study on impact, dimensions and outcome of perceived fatigue in adult 5q-spinal muscular atrophy patients receiving nusinersen treatment
por: Binz, Camilla, et al.
Publicado: (2020)

Growth patterns in children with spinal muscular atrophy
por: De Amicis, Ramona, et al.
Publicado: (2021)

Inclusion body myositis—health-related quality of life and care situation during phases of the “patience journey” in Germany: results from a qualitative study
por: Senn, Katja C., et al.
Publicado: (2023)

Modeling Spinal Muscular Atrophy in Drosophila
por: Chang, Howard Chia-Hao, et al.
Publicado: (2008)

Carrier screening for spinal muscular atrophy
por: Prior, Thomas W.
Publicado: (2008)

Androgens in spinal and bulbar muscular atrophy
Publicado: (2012)

Spinal Muscular Atrophy: The Treatment Approved
por: Tabet, Rabih, et al.
Publicado: (2017)

Advances in spinal muscular atrophy therapeutics
por: Parente, Valeria, et al.
Publicado: (2018)

Euglycemic Ketoacidosis in Spinal Muscular Atrophy
por: Stoimenis, Dimitrios, et al.
Publicado: (2019)

Metabolic Dysfunction in Spinal Muscular Atrophy
por: Deguise, Marc-Olivier, et al.
Publicado: (2021)

Update on Biomarkers in Spinal Muscular Atrophy
por: Pino, Megan G, et al.
Publicado: (2021)

Onasemnogene abeparvovec for spinal muscular atrophy
Publicado: (2022)

Mitochondrial Dysfunction in Spinal Muscular Atrophy
por: Zilio, Eleonora, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_qtfpqn87fug299f47n3uq4tcij